Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Raw Materials (2016 - 2019)

Plus Therapeutics has reported Raw Materials over the past 9 years, most recently at $663000.0 for Q1 2019.

  • Quarterly Raw Materials fell 4.6% to $663000.0 in Q1 2019 from the year-ago period, while the trailing twelve-month figure was $663000.0 through Mar 2019, down 4.6% year-over-year, with the annual reading at $758000.0 for FY2018, 11.31% up from the prior year.
  • Raw Materials was $663000.0 for Q1 2019 at Plus Therapeutics, down from $758000.0 in the prior quarter.
  • Over five years, Raw Materials peaked at $1.7 million in Q1 2015 and troughed at $663000.0 in Q1 2019.
  • The 5-year median for Raw Materials is $907000.0 (2017), against an average of $1.0 million.
  • Year-over-year, Raw Materials skyrocketed 56.58% in 2017 and then tumbled 53.81% in 2018.
  • A 5-year view of Raw Materials shows it stood at $1.0 million in 2015, then decreased by 12.29% to $885000.0 in 2016, then dropped by 23.05% to $681000.0 in 2017, then increased by 11.31% to $758000.0 in 2018, then decreased by 12.53% to $663000.0 in 2019.
  • Per Business Quant, the three most recent readings for PSTV's Raw Materials are $663000.0 (Q1 2019), $758000.0 (Q4 2018), and $698000.0 (Q3 2018).